Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16
| Autor: | Yayrí C. Prieto, Aileen Batte, Milaid Granadillo, Miladys Limonta, Isis Torrens, Enma Brown, Dinorah Torres, Dayana Soler, Laura Varas, Alain B. Alfonso |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
chemistry.chemical_classification lcsh:Immunologic diseases. Allergy business.industry Cell Biological activity Peptide Pharmacology medicine.disease_cause Fusion protein 03 medical and health sciences Titer 030104 developmental biology medicine.anatomical_structure Immunization Antigen chemistry Immunology and Allergy Medicine business lcsh:RC581-607 Escherichia coli |
| Zdroj: | Journal of Cellular Immunotherapy, Vol 4, Iss 2, Pp 71-74 (2018) |
| ISSN: | 2352-1775 |
| Popis: | Cervical cancer is the second leading cause of cancer death in women. It is well established that human papillomavirus (HPV) is the cause of virtually 100% of these cancers, 70% of which are attributable to infections with HPV types 16 or 18. We developed a fusion protein comprising a cell penetrating and immunostimulatory peptide corresponding to residues 32 to 51 of the Limulus polyphemus protein (LALF32-51) linked to the HPV16 E7 antigen (LALF32-51–E7) that is obtained from Escherichia coli. The development of new treatments as mentioned requires a robust and reproducible procedure for batch release. We used the combination of three batches of LALF32-51-E7 with Al(OH)3 in an experimental design to develop a biological activity test for batch release of this candidate, which uses prophylactic immunization in the TC-1 tumor mouse model. Two injections, spaced for 7 days with LALF31-52-E7+Al(OH)3 are sufficient for inducing a potent anti-tumor response in the TC-1 tumor model. LALF31-52-E7 vaccine candidates in combination with Al(OH)3, exhibited in C57BL/6 mice over 86% protection against tumor challenge and high titers of specific antibodies against LALF31-52-E7. The results obtained across three batches of LALF32-51–E7+Al(OH)3 with this simple and uncomplicated assay based on prophylactic immunization in the TC-1 mouse model suggest that it would be feasible to implement it as a biological activity assay for the release of production batches of LALF32-51–E7. Keywords: Cervical cancer, LALF32-51-E7, HPV16, TC-1 tumor model, Batch release |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|